BridgeBio Oncology Therapeutics, Inc. SEC filings BBOT
BridgeBio Oncology Therapeutics, Inc. has 185 filings in SEC EDGAR's recent list, going back to Dec 20, 2023. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 5, 2026 | Oct 30, 2026 |
| EFFECT | Filing | Sep 10, 2026 | — |
| EFFECT | Filing | Sep 8, 2026 | — |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| S-3 | Shelf registration | Sep 1, 2026 | — |
| POS AM | Filing | Sep 1, 2026 | — |
| 424B3 | Prospectus | Aug 12, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 424B3 | Prospectus | Jun 22, 2026 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 22, 2026 | Jun 16, 2026 |
| 424B3 | Prospectus | May 13, 2026 | — |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 424B3 | Prospectus | May 6, 2026 | — |
| EFFECT | Filing | May 4, 2026 | — |
| POS AM | Filing | Apr 30, 2026 | — |
| 424B3 | Prospectus | Apr 29, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Apr 29, 2026 | Apr 27, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 16, 2026 |
| 424B3 | Prospectus | Apr 23, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 23, 2026 | Apr 20, 2026 |
| 424B3 | Prospectus | Mar 26, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Mar 26, 2026 | Mar 24, 2026 |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 424B3 | Prospectus | Jan 7, 2026 | — |
| 424B3 | Prospectus | Jan 7, 2026 | — |
| 8-K |
Current report
Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| S-8 | Employee stock plan registration | Jan 2, 2026 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| S-8 | Employee stock plan registration | Oct 10, 2025 | — |
| EFFECT | Filing | Sep 10, 2025 | — |
| 424B3 | Prospectus | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Sep 8, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2025 | — |
| S-1 | Registration statement | Aug 29, 2025 | — |
| EFFECT | Filing | Aug 19, 2025 | — |
| POS AM | Post-effective amendment no. 1 to form s-4 | Aug 15, 2025 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Aug 13, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2025 | Aug 6, 2025 |
| 425 | Current report | Aug 4, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Aug 4, 2025 | Aug 4, 2025 |
| 10-Q | Quarterly report | Aug 1, 2025 | Jun 30, 2025 |
| 424B3 | Prospectus | Jul 22, 2025 | — |
| 425 | Form 425 | Jul 21, 2025 | — |
| 425 | Current report | Jul 11, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 11, 2025 | Jul 11, 2025 |
| EFFECT | Filing | Jul 10, 2025 | — |
| 424B4 | Prospectus | Jul 10, 2025 | — |
| CORRESP | Letter to the SEC | Jul 9, 2025 | — |
| S-4/A | Registration statement | Jul 9, 2025 | — |
| CORRESP | Letter to the SEC | Jul 1, 2025 | — |
| S-4/A | Registration statement | Jul 1, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2025 | — |
| CORRESP | Letter to the SEC | Jun 20, 2025 | — |
| S-4 | Registration for a merger or exchange | Jun 20, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2025 | — |
| DRSLTR | Filing | May 30, 2025 | — |
| DRS/A | Filing | May 30, 2025 | — |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| UPLOAD | Letter from the SEC | May 13, 2025 | — |
| DRS | Filing | Apr 15, 2025 | — |
| DRSLTR | Filing | Apr 14, 2025 | — |
| 10-K | Annual report | Mar 11, 2025 | Dec 31, 2024 |
| 425 | Form 425 | Mar 6, 2025 | — |
| 425 | Current report | Mar 3, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 3, 2025 | Feb 28, 2025 |
| 425 | Current report | Feb 28, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 28, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 10, 2025 | Feb 8, 2025 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Other events
|
Feb 20, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Feb 14, 2024 | Feb 8, 2024 |
| 424B4 | Prospectus | Feb 13, 2024 | — |
| EFFECT | Filing | Feb 8, 2024 | — |
| S-1MEF | Registration statement | Feb 8, 2024 | — |
| CERT | Filing | Feb 8, 2024 | — |
| 8-A12B | For registration of certain classes | Feb 8, 2024 | — |
| CORRESP | Letter to the SEC | Feb 7, 2024 | — |
| CORRESP | Letter to the SEC | Feb 7, 2024 | — |
| S-1/A | Amended registration statement | Feb 7, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 2, 2024 | — |
| S-1/A | Amended registration statement | Feb 2, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| S-1 | Registration statement | Jan 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2024 | — |
| DRS | Filing | Dec 20, 2023 | — |
Showing 97 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBOT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1869105
- Former names
- Helix Acquisition Corp. II (until Aug 6, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.